Oncology

Oncology Review CME / CPD 

Full Course:  20 AMA PRA Category 1 Credits for CME / CEU / CPD

Short Course:  10 AMA PRA Category 1 Credits for CME / CEU / CPD

Course(s) are appropriate for:   Family Practitioners, Pediatricians, Internists, General Practitioners, Nurses, Nurse Practitioners, Physician Assistants (PA-C's)

Series 39 (ONC39) Topics Include:  Common Types of Salivary Gland Tumors, Multimodal Therapy for Prostate Cancer, Characteristics of Microsatellite Instability-High Colorectal Cancer, MCL, Whole-Brain Radiation Therapy, and more.

To view topic outline of the full or short course, select the Course Type (Full or Short) below:

Full Course:
ONC39
Full Course Price:
$580
Short Course:
ONC39A, ONC97B
Short Course Price:
$485
Format:
Available in Audio format.

Course Topics

New Developments in Head and Neck Cancer

Explain why targets of immunotherapy are more difficult to identify in cancers of the head and neck than in melanoma; Identify the role of targeted therapies in treatment of patients with cancers of the head and neck; Evaluate the 2 methods for detection of neoantigens; Use targeted agents in treating patients with tumors of the salivary glands; Distinguish the main features of the molecular signatures of common types of salivary gland tumors.

Mantle Cell Lymphoma

Use prognostic markers for risk stratification in patients with MCL; Identify patients with MCL who are likely to benefit from deferred therapy; Select an induction chemotherapy regimen for MCL based on the age and fitness of the patient; Compare the efficacies and toxicities of agents commonly used to treat relapsed MCL; Assess the relationship between dose or duration of therapy and toxicity for drugs used to treat relapsed MCL.

QUALIFIES FOR CLINICAL PHARMACOLOGY

Highlights from Scripps' 38th Annual Conference: Clinical Hematology and Oncology 2018

Compare the characteristics and prognosis between human papillomavirus (HPV)-positive and HPV-negative head and neck cancer; Summarize the efficacy and toxicity of chemotherapy and radiation therapy for high-risk and locally advanced head and neck cancer; Identify factors associated with response to immunotherapy in metastatic head and neck cancer; Discuss the relationship between risk scores from multiparameter genomic assays for breast cancer and patient outcomes; Explain how spatial heterogeneity within a tumor and temporal heterogeneity between a primary breast tumor and distant metastases affect response to therapy.

QUALIFIES FOR CLINICAL PHARMACOLOGY

Highlights from the State of the Art Management of Lung Cancer Symposium

Plan treatment for a patient with limited-stage small-cell lung cancer; Counsel patients based on the outcomes of trials that compared cisplatin with carboplatin as treatment for small-cell lung cancer; Explain the mechanism of action of targeted therapies currently under investigation for treatment of small-cell lung cancer; List the benefits of early palliative care in patients with lung cancer; Manage simultaneous presentation of multiple symptoms during therapy for lung cancer.

Brachytherapy for Prostate Cancer

Define calculations of volume commonly used for planning brachytherapy treatment to the prostate; Select appropriate candidates for low dose rate brachytherapy to the prostate; List the advantages of high dose rate brachytherapy over low dose rate brachytherapy for treatment of prostate cancer; Summarize the important findings reported in the ASCENDE-RT trial; Counsel a patient considering multimodal therapy for prostate cancer about common toxicities and associated risk factors.

Brain Metastases

Identify primary malignancies and molecular subtypes commonly associated with brain metastases; Review the efficacy and toxicities of radiation therapy, surgery, radiosurgery, and chemotherapy for treating brain metastases; Compare and contrast the efficacy and safety of whole-brain radiation therapy and stereotactic radiosurgery for the management of brain metastases; Summarize the efficacy of new-generation targeted therapies and immunotherapies for inducing an intracranial response; Discuss the genetic alterations that occur between primary tumors, brain and extracranial metastases, and lymph nodes.

Update on Breast Cancer Surgery

Reduce the false-negative rate of sentinel lymph node biopsy after neoadjuvant chemotherapy; Perform lymph node biopsy using targeted axillary dissection; Adopt consensus guidelines for adequate surgical margins in patients with invasive breast cancer and ductal carcinoma in situ; Lower the risk for local recurrence in patients with ductal carcinoma in situ; Recognize the role of the radiologist in the treatment of patients with breast cancer.

Gastric Cancer/Testis Cancer

Choose appropriate methods for diagnosis and staging of gastric cancer; Discuss the roles of chemotherapy and radiation therapy for resectable and metastatic gastric, gastroesophageal junction, and esophageal cancers; Identify characteristics of 4 genomic subsets of upper gastrointestinal cancers and how they differ in response to targeted therapies and immunotherapy drugs; Select a management strategy for testis cancer based on risk factors; Use serum tumor markers to risk-stratify disseminated testicular cancer and assess response to treatment.

Highlights from the 6th Annual Experimental Therapeutics in Oncology: The Road to Personalized Medicine

Differentiate immune-related adverse events from disease progression or infectious complications; Utilize laboratory testing to monitor for early signs of immune-related adverse events; Implement management strategies for immune-related adverse events based on severity of reaction; Explain why the efficacy of targeted therapies varies among different types of malignancies; Identify characteristics of microsatellite instability-high colorectal cancer.

Frontiers in Precision Medicine for Inherited Cancers: From Risk Assessment to Targeted Therapies

Identify common germline mutations in mismatch repair genes associated with prostate cancer; Compare the prevalence of germline mutations in high-risk metastatic, high-risk localized, and low-risk prostate cancer; Summarize the prevalence and distribution of genes for susceptibility to hereditary cancer in patients with early onset colorectal cancer; Classify gene mutations and clinical disorders associated with myelodysplastic syndromes; List possible indications that a case of myeloid leukemia has a familial component.

New Developments in Head and Neck Cancer

Explain why targets of immunotherapy are more difficult to identify in cancers of the head and neck than in melanoma; Identify the role of targeted therapies in treatment of patients with cancers of the head and neck; Evaluate the 2 methods for detection of neoantigens; Use targeted agents in treating patients with tumors of the salivary glands; Distinguish the main features of the molecular signatures of common types of salivary gland tumors.

Highlights from the State of the Art Management of Lung Cancer Symposium

Plan treatment for a patient with limited-stage small-cell lung cancer; Counsel patients based on the outcomes of trials that compared cisplatin with carboplatin as treatment for small-cell lung cancer; Explain the mechanism of action of targeted therapies currently under investigation for treatment of small-cell lung cancer; List the benefits of early palliative care in patients with lung cancer; Manage simultaneous presentation of multiple symptoms during therapy for lung cancer.

Brachytherapy for Prostate Cancer

Define calculations of volume commonly used for planning brachytherapy treatment to the prostate; Select appropriate candidates for low dose rate brachytherapy to the prostate; List the advantages of high dose rate brachytherapy over low dose rate brachytherapy for treatment of prostate cancer; Summarize the important findings reported in the ASCENDE-RT trial; Counsel a patient considering multimodal therapy for prostate cancer about common toxicities and associated risk factors.

Update on Breast Cancer Surgery

Reduce the false-negative rate of sentinel lymph node biopsy after neoadjuvant chemotherapy; Perform lymph node biopsy using targeted axillary dissection; Adopt consensus guidelines for adequate surgical margins in patients with invasive breast cancer and ductal carcinoma in situ; Lower the risk for local recurrence in patients with ductal carcinoma in situ; Recognize the role of the radiologist in the treatment of patients with breast cancer.

Highlights from the 6th Annual Experimental Therapeutics in Oncology: The Road to Personalized Medicine

Differentiate immune-related adverse events from disease progression or infectious complications; Utilize laboratory testing to monitor for early signs of immune-related adverse events; Implement management strategies for immune-related adverse events based on severity of reaction; Explain why the efficacy of targeted therapies varies among different types of malignancies; Identify characteristics of microsatellite instability-high colorectal cancer.

Mantle Cell Lymphoma

Use prognostic markers for risk stratification in patients with MCL; Identify patients with MCL who are likely to benefit from deferred therapy; Select an induction chemotherapy regimen for MCL based on the age and fitness of the patient; Compare the efficacies and toxicities of agents commonly used to treat relapsed MCL; Assess the relationship between dose or duration of therapy and toxicity for drugs used to treat relapsed MCL.

QUALIFIES FOR CLINICAL PHARMACOLOGY

Highlights from Scripps' 38th Annual Conference: Clinical Hematology and Oncology 2018

Compare the characteristics and prognosis between human papillomavirus (HPV)-positive and HPV-negative head and neck cancer; Summarize the efficacy and toxicity of chemotherapy and radiation therapy for high-risk and locally advanced head and neck cancer; Identify factors associated with response to immunotherapy in metastatic head and neck cancer; Discuss the relationship between risk scores from multiparameter genomic assays for breast cancer and patient outcomes; Explain how spatial heterogeneity within a tumor and temporal heterogeneity between a primary breast tumor and distant metastases affect response to therapy.

QUALIFIES FOR CLINICAL PHARMACOLOGY

Brain Metastases

Identify primary malignancies and molecular subtypes commonly associated with brain metastases; Review the efficacy and toxicities of radiation therapy, surgery, radiosurgery, and chemotherapy for treating brain metastases; Compare and contrast the efficacy and safety of whole-brain radiation therapy and stereotactic radiosurgery for the management of brain metastases; Summarize the efficacy of new-generation targeted therapies and immunotherapies for inducing an intracranial response; Discuss the genetic alterations that occur between primary tumors, brain and extracranial metastases, and lymph nodes.

Gastric Cancer/Testis Cancer

Choose appropriate methods for diagnosis and staging of gastric cancer; Discuss the roles of chemotherapy and radiation therapy for resectable and metastatic gastric, gastroesophageal junction, and esophageal cancers; Identify characteristics of 4 genomic subsets of upper gastrointestinal cancers and how they differ in response to targeted therapies and immunotherapy drugs; Select a management strategy for testis cancer based on risk factors; Use serum tumor markers to risk-stratify disseminated testicular cancer and assess response to treatment.

Frontiers in Precision Medicine for Inherited Cancers: From Risk Assessment to Targeted Therapies

Identify common germline mutations in mismatch repair genes associated with prostate cancer; Compare the prevalence of germline mutations in high-risk metastatic, high-risk localized, and low-risk prostate cancer; Summarize the prevalence and distribution of genes for susceptibility to hereditary cancer in patients with early onset colorectal cancer; Classify gene mutations and clinical disorders associated with myelodysplastic syndromes; List possible indications that a case of myeloid leukemia has a familial component.

Additional Information

Additional Continuing Medical Education options available:

Other courses of interest may include:  SurgeryFamily PracticeInternal MedicineObesity and Nutrition.

If you have taken the current Oncology CME / CPD Review listed above or if you are seeking additional credits, please visit: Medical Courses Coming Soon There you will find abbreviated listings of additional courses available related to this specialty and courses that are soon to be released.

For over 30 years, ASI has provided Continuing Medical Education, CME & CEU and Continuing Professional Development Education (CPD) for physicians and allied professionals in Oncology plus over 40 other specialties and subspecialties.  Lectures are recorded annually at the top seminars and conferences to provide the most current medical education to our clients.